非布索坦的注意事项有哪些呢？

It was developed in Japan in 2004, approved for marketing by European EMEA in 2008, approved for marketing by the US FDA in 2009, and approved for marketing by the China State Food and Drug Administration in 2013. Let’s take a look at the precautions for febuxostat?

Cardiovascular events In randomized controlled studies, patients treated with febuxostat had a higher rate of cardiovascular thrombotic events (including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) than allopurinol, with febuxostat being 0.74/100 patient-years (95%CI: 0.36-1.37) and allopurinol being 0.60/100 patient-years (95%CI: 0.16-1.53). A causal relationship between febuxostat and cardiovascular thrombotic events has not been established. Pay attention to monitor the symptoms and signs of myocardial infarction and stroke when taking the drug. Although there is insufficient information within these reports to establish a causal relationship between them. In randomized controlled studies, it was observed that transaminases could increase to more than 3 times the upper limit of normal range (ULN) (the incidence rates in febuxostat and allopurinol treatment groups were AST: 2%, 2%; ALT: 3%, 2%). 

There was no dose-response relationship for these aminotransferase elevations. Patients should have a liver function test (serum alanine aminotransferase, aspartate transferase, alkaline phosphatase, and total bilirubin) performed before first starting febuxostat and use this result as a baseline level. Patients who report symptoms such as fatigue, loss of appetite, right upper quadrant discomfort, soy-colored urine, or jaundice that may indicate liver damage should undergo prompt liver function testing. 

On the clinical side, if a patient is found to have abnormal liver function (ALT more than 3 times the upper limit of the reference range), the medication should be discontinued and investigated to determine the possible cause. Febuxostat should not be reintroduced in these patients who have abnormal liver function tests and no other reasonable explanation. If the patient's serum ALT exceeds more than 3 times the reference range, and the serum total bilirubin exceeds more than 2 times the reference range, and other causes are excluded, the patient is at risk of severe drug-induced liver damage, and these patients should not restart febuxostat.

The above are some things that patients need to pay attention to when using it to treat gout. If the above serious conditions occur, please consult a doctor in time.